Stratasys (SSYS)
(Delayed Data from NSDQ)
$8.91 USD
+0.05 (0.56%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $8.90 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
SSYS 8.91 +0.05(0.56%)
Will SSYS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SSYS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SSYS
Implied Volatility Surging for Stratasys (SSYS) Stock Options
Stratasys (SSYS) Launches New Dental 3D Printer DentaJet XL
SSYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Stratasys (SSYS) Down 7% Since Last Earnings Report: Can It Rebound?
Stratasys (SSYS) Tests 3D Printed Models in Orthopedic Oncology
Stratasys (SSYS), AM Craft to Venture Into the Aviation Industry
Other News for SSYS
Stratasys unveils the DentaJet? XL solution, designed to transform production of high-quality models for crowns and bridges, implants, clear aligner arches, and surgical guides
Stratasys Recognized at AMGTA Member Summit with Four Awards for Excellence in Additive Manufacturing Sustainable Business Practices
First patient enrolled in landmark clinical study to assess 3D printed models for orthopedic tumor removal
First Patient Enrolled in Landmark Clinical Study to Assess3D Printed Models for Orthopedic Tumor Removal
Stratasys enrolls first patient in orthopedic oncology 3D printed model study